WINTON GROUP Ltd Purchases 28,602 Shares of Contineum Therapeutics, Inc. (NASDAQ:CTNM)

WINTON GROUP Ltd lifted its position in Contineum Therapeutics, Inc. (NASDAQ:CTNM) by 256.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 39,738 shares of the company’s stock after purchasing an additional 28,602 shares during the quarter. WINTON GROUP Ltd’s holdings in Contineum Therapeutics were worth $582,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in CTNM. Corebridge Financial Inc. grew its position in Contineum Therapeutics by 73.1% during the fourth quarter. Corebridge Financial Inc. now owns 5,215 shares of the company’s stock worth $76,000 after buying an additional 2,202 shares in the last quarter. BNP Paribas Financial Markets increased its position in Contineum Therapeutics by 1,248.6% during the 3rd quarter. BNP Paribas Financial Markets now owns 6,743 shares of the company’s stock valued at $129,000 after purchasing an additional 6,243 shares during the period. Rhumbline Advisers increased its position in Contineum Therapeutics by 36.3% during the 4th quarter. Rhumbline Advisers now owns 8,233 shares of the company’s stock valued at $121,000 after purchasing an additional 2,191 shares during the period. Barclays PLC raised its holdings in Contineum Therapeutics by 248.6% in the 3rd quarter. Barclays PLC now owns 8,308 shares of the company’s stock worth $158,000 after purchasing an additional 5,925 shares in the last quarter. Finally, Bank of New York Mellon Corp lifted its position in shares of Contineum Therapeutics by 32.3% in the 4th quarter. Bank of New York Mellon Corp now owns 18,738 shares of the company’s stock worth $275,000 after purchasing an additional 4,573 shares during the period.

Contineum Therapeutics Stock Performance

CTNM stock opened at $7.07 on Friday. The firm has a 50 day moving average price of $8.23 and a 200-day moving average price of $13.24. Contineum Therapeutics, Inc. has a 52-week low of $5.92 and a 52-week high of $22.00. The firm has a market capitalization of $182.92 million and a price-to-earnings ratio of -1.44.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the stock. Jones Trading initiated coverage on shares of Contineum Therapeutics in a research report on Thursday, March 13th. They set a “buy” rating and a $23.00 price target on the stock. Robert W. Baird reduced their target price on Contineum Therapeutics from $32.00 to $16.00 and set an “outperform” rating on the stock in a report on Friday, March 7th. Morgan Stanley restated an “overweight” rating and issued a $25.00 target price on shares of Contineum Therapeutics in a research note on Friday, March 7th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $31.00 price target on shares of Contineum Therapeutics in a research note on Thursday, January 9th. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Contineum Therapeutics presently has an average rating of “Buy” and a consensus price target of $24.80.

About Contineum Therapeutics

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS).